Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
To take it back to where it started. No company making a bit of ‘bread and butter’ money from producing an out of patent Chemotherapy is going to sabotage or put pressure on clinicians if a better alternative comes along. They would be much keener in partnering to develop it or even manufacture it.
Come on Viking raider. You can do better than that. With a name like Viking raider you should be ‘ I’ve remortgaged my house and I’m all in’ or ‘ I’m going to short thus mofo down to 30p you fools’. This is more Cruise on the fjords, must try harder
Currently Dox is off patent Oily. Just bringing it back under patent again would be huge for any big Pharma. That alone should be enough to assuage your ‘concerns’. With less side affects a broader population could be treated with it, think kids, the elderly people with Co-morbidity.
That’s no coincidence, trained by Ophidian, ridden by Hurst. Hurst will borrow Ophidians Chorizo to help whip ‘Rumours are flying’ over the line, bang in time for the 3pm mega RNS. The clues are all there, just too stupid to see them
Is Hurst Ophidians mole stateside? If only I was more cleverer the writing on the wall is clear to see. So Bego are on the bid, NY size orders and by now New York are tucking into lunch. We used to have the perfect guy on this board a couple of years ago. Poirot, where are you now? The plebs need you to unravel Hursts coded language and Ophidians mystic clues. I was labouring under the misapprehension that one was a semi functional chatbot the other a semi functional charlatan, are they onto something, please Poirot save us..
It’s looking like 2 rich, a short dose escalation one then a registrational P2. Drug could be on the market in 2 years. Might seem like a long time but in pharma terms that’s near term. Drugs take between 10-15 years to develop. It seems likely Ava6000 may get an accelerated approval at some point that may shorten these timescales
In answer, curtesy of ChatGPT,to your poor attempt at fud Eggy
Lead investigators involved in clinical trials generally refrain from making public comments about the trial's results until the study is complete and the findings have been thoroughly analyzed. Premature disclosure of incomplete or interim data can be misleading and may not accurately represent the final outcome.
Once the trial is concluded, lead investigators often publish their results in scientific journals and may participate in press releases or conferences to communicate the findings to the public and the scientific community. This ensures that the information is presented accurately, in context, and has undergone the necessary peer review.
Public communication about ongoing clinical trials is typically managed carefully to maintain scientific integrity and avoid potential misconceptions or premature conclusions about a drug's efficacy and safety.